Story · Brazil
Aurobindo arm CuraTeQ Biologics’ facility secures nod from Brazil’s health regulator
Aurobindo Pharma's subsidiary CuraTeQ Biologics has received approval from Brazil's health regulator Anvisa for its biosimilars manufacturing facility in Hyderabad, India. The facility underwent a Good Manufacturing Practice (GMP) inspection by Anvisa from May 11-15, 2026, covering four biosimilar products, mammalian and microbial drug substance manufacturing, prefillable syringe and vial filling, packaging, labeling, and QC testing. The approval enables CuraTeQ to enter the broader Latin American market. The facility is already certified by the European Medicines Agency (EMA) and the World Health Organization (WHO), underscoring its global compliance standards.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection